Effects of TT and 9CTT in Combination With VD3 on Growth Inhibition and Differentiation of Human Promyelocytic Leukemia NB4 Cells
| Treatment . | Growth Inhibition (% of control) . | Lysozyme (U/106 cells) . | CD11b (%) . | CD14 (%) . | Esterase3-150 (%) . |
|---|---|---|---|---|---|
| None | 100 | 0.20 ± 0.01 | 46 ± 5 | 30 ± 4 | 2 ± 1 |
| TT | 113 ± 2 | 0.06 ± 0.01 | 59 ± 1 | 28 ± 4 | 2 ± 1 |
| 9CTT | 122 ± 4 | 0.06 ± 0.01 | 62 ± 6 | 30 ± 4 | 3 ± 1 |
| VD3 | 73 ± 4 | 0.33 ± 0.08 | 83 ± 1 | 33 ± 4 | 15 ± 3 |
| VD3 + TT | 40 ± 3 | 0.85 ± 0.14 | 82 ± 1 | 38 ± 4 | 16 ± 1 |
| VD3 + 9CTT | 19 ± 3 | 2.65 ± 0.42 | 72 ± 2 | 53 ± 4 | 48 ± 2 |
| Treatment . | Growth Inhibition (% of control) . | Lysozyme (U/106 cells) . | CD11b (%) . | CD14 (%) . | Esterase3-150 (%) . |
|---|---|---|---|---|---|
| None | 100 | 0.20 ± 0.01 | 46 ± 5 | 30 ± 4 | 2 ± 1 |
| TT | 113 ± 2 | 0.06 ± 0.01 | 59 ± 1 | 28 ± 4 | 2 ± 1 |
| 9CTT | 122 ± 4 | 0.06 ± 0.01 | 62 ± 6 | 30 ± 4 | 3 ± 1 |
| VD3 | 73 ± 4 | 0.33 ± 0.08 | 83 ± 1 | 33 ± 4 | 15 ± 3 |
| VD3 + TT | 40 ± 3 | 0.85 ± 0.14 | 82 ± 1 | 38 ± 4 | 16 ± 1 |
| VD3 + 9CTT | 19 ± 3 | 2.65 ± 0.42 | 72 ± 2 | 53 ± 4 | 48 ± 2 |
Cells (5 × 104 cells were incubated with 3 × 10−6 mol/L TT or 9CTT in the absence or presence of 3 × 10−7 mol/L VD3 for 4 days. Values represent the means ± SD of three separate experiments.
α-Naphthyl acetate esterase positive cells were counted.